Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda has completed its acquisition of Recip AB. Meda receives product rights and brands, rights to the name Recip, and it takes over existing sales operations.
Subscribe to our email newsletter
The product portfolio consists of well-established pharmaceuticals such as Kavepenin, Heracillin, Kalcipos, and TrioBe. The acquisition is said to strengthen Meda’s home base in Sweden, and new product opportunities from Recip’s product portfolio can be commercialized outside the Nordics. Considerable synergy effects are also expected.
The acquisition price for all shares in Recip AB was SEK2.65 billion on a debt-free basis plus SEK5.7 million newly issued shares in Meda AB. The net debt that Meda took over totaled SEK832 million. Meda’s cash payment was SEK1.81 billion, totally financed within existing credit facilities. The price for the newly issued shares was set at SEK86.25 per share.